Axonics Expects FY23 Revenues Of Approximately $366.1M, Up 34% Y/Y Versus Consensus Of $362.27M
Portfolio Pulse from Benzinga Newsdesk
Axonics anticipates its FY23 revenues to be around $366.1M, marking a 34% year-over-year increase, which slightly exceeds the consensus estimate of $362.27M. The company expects sacral neuromodulation revenue to grow by 31% to $291.7M and Bulkamid revenue to increase by 44% to $74.4M compared to fiscal year 2022.
January 08, 2024 | 12:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Axonics expects FY23 revenues to surpass expectations at $366.1M, with significant growth in sacral neuromodulation and Bulkamid sales.
The positive revenue forecast for Axonics, especially with the expected growth in sacral neuromodulation and Bulkamid sales, is likely to be viewed favorably by investors. The fact that the projected revenue exceeds consensus estimates suggests that the company is performing better than expected, which could lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100